VA
ORKA

VR Adviser’s Oruka Therapeutics ORKA Stock Holding History

VR Adviser’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$203M Hold
4,148,428
– – 7.6% 3
2025
Q4 		$126M Hold
4,148,428
– – 6.21% 2
2025
Q3 		$79.8M Hold
4,148,428
– – 4.49% 7
2025
Q2 		$46.5M Hold
4,148,428
– – 3.48% 8
2025
Q1 		$42.6M Buy
4,148,428
+862,808
+26% +$10.8M 3.62% 9
2024
Q4 		$63.7M Buy
3,285,620
+200,000
+6% +$4.88M 4.37% 6
2024
Q3 		$75.6M Buy
3,085,620
+3,013,422
+4,174% +$105M 3.96% 8
2024
Q2 		$3.32M Buy
+72,198
New +$2.88M 0.21% 34

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VR Adviser's ORKA Position: Q1 2026 in Review

VR Adviser held its Oruka Therapeutics (ORKA) position steady in Q1 2026 at 4,148,428 shares worth $203M. The position accounts for 7.6% of the portfolio, ranked #3.

VR Adviser first reported a position in ORKA in Q2 2024 and has held it in 8 quarters since. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • VR Adviser held 4,148,428 shares of Oruka Therapeutics worth $203M as of Q1 2026.
  • VR Adviser left its Oruka Therapeutics share count unchanged in Q1 2026.
  • Oruka Therapeutics made up 7.6% of VR Adviser's portfolio in Q1 2026, its #3 holding.
  • VR Adviser first reported a position in Oruka Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on VR Adviser's 13F filing for Q1 2026, filed 15 May 2026.